Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
about
What can nanosafety learn from drug development? The feasibility of "safety by design".Human ex-vivo action potential model for pro-arrhythmia risk assessment.Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential Variability.Integrated TK-TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs.
P2860
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
@en
type
label
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
@en
prefLabel
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
@en
P2860
P50
P1433
P1476
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
@en
P2093
Michael K Pugsley
Norman Stockbridge
P2860
P2888
P304
P356
10.1208/S12248-015-9773-1
P407
P577
2015-05-05T00:00:00Z
P5875
P6179
1021229112